Xin Jin, Jacques Pirenne, Robin Vos, Charlotte Hooft, Janne Kaes, Jan Van Slambrouck, Phéline Kortleven, Christelle Vandervelde, Hanne Beeckmans, Pieterjan Kerckhof, Marianne S Carlon, Dirk Van Raemdonck, Mark R Looney, Bart M Vanaudenaerde, Laurens J Ceulemans
{"title":"肺移植中的捐献者特异性输血。","authors":"Xin Jin, Jacques Pirenne, Robin Vos, Charlotte Hooft, Janne Kaes, Jan Van Slambrouck, Phéline Kortleven, Christelle Vandervelde, Hanne Beeckmans, Pieterjan Kerckhof, Marianne S Carlon, Dirk Van Raemdonck, Mark R Looney, Bart M Vanaudenaerde, Laurens J Ceulemans","doi":"10.3389/ti.2024.12822","DOIUrl":null,"url":null,"abstract":"<p><p>Lung transplantation is still hindered by a high rate of chronic rejection necessitating profound immunosuppression with its associated complications. Donor-specific blood transfusion is a pre-transplant strategy aimed at improving graft acceptance. In contrast with standard stored blood or donor-specific regulatory T cells transfusions, this approach utilizes fresh whole blood from the donor prior to allograft transplantation, encompassing all cell types and plasma. The precise mechanisms underlying donor-specific blood transfusion-induced tolerance remain incompletely understood. Associations with regulatory/helper T cells, modulation of mononuclear phagocytic cells or microchimerism have been suggested. While numerous (pre-)clinical studies have explored its application in solid organ transplants like liver, kidney, and intestine, limited attention has been given to the setting of lung transplantation. This comprehensive review summarizes existing knowledge on the mechanisms and outcomes of donor-specific blood transfusion in solid organ transplants both in preclinical and clinical settings. We also address the potential benefits and risks associated with donor-specific blood transfusion in the field of lung transplantation, offering insights into future research directions.</p>","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"12822"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565953/pdf/","citationCount":"0","resultStr":"{\"title\":\"Donor-Specific Blood Transfusion in Lung Transplantation.\",\"authors\":\"Xin Jin, Jacques Pirenne, Robin Vos, Charlotte Hooft, Janne Kaes, Jan Van Slambrouck, Phéline Kortleven, Christelle Vandervelde, Hanne Beeckmans, Pieterjan Kerckhof, Marianne S Carlon, Dirk Van Raemdonck, Mark R Looney, Bart M Vanaudenaerde, Laurens J Ceulemans\",\"doi\":\"10.3389/ti.2024.12822\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lung transplantation is still hindered by a high rate of chronic rejection necessitating profound immunosuppression with its associated complications. Donor-specific blood transfusion is a pre-transplant strategy aimed at improving graft acceptance. In contrast with standard stored blood or donor-specific regulatory T cells transfusions, this approach utilizes fresh whole blood from the donor prior to allograft transplantation, encompassing all cell types and plasma. The precise mechanisms underlying donor-specific blood transfusion-induced tolerance remain incompletely understood. Associations with regulatory/helper T cells, modulation of mononuclear phagocytic cells or microchimerism have been suggested. While numerous (pre-)clinical studies have explored its application in solid organ transplants like liver, kidney, and intestine, limited attention has been given to the setting of lung transplantation. This comprehensive review summarizes existing knowledge on the mechanisms and outcomes of donor-specific blood transfusion in solid organ transplants both in preclinical and clinical settings. We also address the potential benefits and risks associated with donor-specific blood transfusion in the field of lung transplantation, offering insights into future research directions.</p>\",\"PeriodicalId\":23343,\"journal\":{\"name\":\"Transplant International\",\"volume\":\"37 \",\"pages\":\"12822\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565953/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transplant International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/ti.2024.12822\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/ti.2024.12822","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
由于慢性排斥反应的发生率较高,肺移植手术仍然受到很大的阻碍,因此必须进行深度免疫抑制及其相关并发症。捐献者特异性输血是一种旨在提高移植接受度的移植前策略。与标准的储存血或捐献者特异性调节 T 细胞输血不同,这种方法是在异体移植前使用捐献者的新鲜全血,包括所有细胞类型和血浆。捐献者特异性输血诱导耐受的确切机制仍不完全清楚。有人认为这与调节性/辅助性 T 细胞、单核吞噬细胞或微嵌合体的调节有关。虽然许多(预)临床研究都探讨了其在肝脏、肾脏和肠道等实体器官移植中的应用,但对肺移植的关注却很有限。本综述总结了临床前和临床环境中有关供体特异性输血在实体器官移植中的机制和结果的现有知识。我们还探讨了肺移植领域中与供体特异性输血相关的潜在益处和风险,并对未来的研究方向提出了见解。
Donor-Specific Blood Transfusion in Lung Transplantation.
Lung transplantation is still hindered by a high rate of chronic rejection necessitating profound immunosuppression with its associated complications. Donor-specific blood transfusion is a pre-transplant strategy aimed at improving graft acceptance. In contrast with standard stored blood or donor-specific regulatory T cells transfusions, this approach utilizes fresh whole blood from the donor prior to allograft transplantation, encompassing all cell types and plasma. The precise mechanisms underlying donor-specific blood transfusion-induced tolerance remain incompletely understood. Associations with regulatory/helper T cells, modulation of mononuclear phagocytic cells or microchimerism have been suggested. While numerous (pre-)clinical studies have explored its application in solid organ transplants like liver, kidney, and intestine, limited attention has been given to the setting of lung transplantation. This comprehensive review summarizes existing knowledge on the mechanisms and outcomes of donor-specific blood transfusion in solid organ transplants both in preclinical and clinical settings. We also address the potential benefits and risks associated with donor-specific blood transfusion in the field of lung transplantation, offering insights into future research directions.
期刊介绍:
The aim of the journal is to serve as a forum for the exchange of scientific information in the form of original and high quality papers in the field of transplantation. Clinical and experimental studies, as well as editorials, letters to the editors, and, occasionally, reviews on the biology, physiology, and immunology of transplantation of tissues and organs, are published. Publishing time for the latter is approximately six months, provided major revisions are not needed. The journal is published in yearly volumes, each volume containing twelve issues. Papers submitted to the journal are subject to peer review.